Several life sciences hedge funds are on a two-month winning streak, raising investor hopes that the sector has truly bottomed after suffering sharp losses over the past year and a half.
One significant reason for the resurgence is the belief — or at least the hope — that recent acquisitions of biotech companies by big pharma will help spark a resurgence in other life sciences stocks.
For
